Search clinical trials for: XPO1

Total 9 results

Chinese PLA General Hospital

Recruiting

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

Advanced Lymphoma | Newly Diagnosed | nk/T-cell Lymphoma

China
Ruijin Hospital

Recruiting

A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma

Lymphoma | DLBCL | T Cell Lymphoma

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Solid Tumor | Rhabdoid Tumor | Wilms Tumor | Nephroblastoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | XPO1 Gene Mutation

United States
Peking University People's Hospital
Beijing Hospital

Unknown

Treatment of Chronic Lymphocytic Leukemia

Leukemia, Lymphocytic, Chronic, B-Cell
Centre Henri Becquerel

Unknown

Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma (XPO1)

Classical Hodgkin Lymphoma

France
Shanghai Tong Ren Hospital

Recruiting

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia (SAV)

AML, Adult

China
Stemline Therapeutics, Inc.

Completed

A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors

Solid Tumors

United States
Shanghai Tong Ren Hospital

Recruiting

Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results (AVS)

AML | MRD

China
Sun Yat-sen University
Fudan University; Antengene Corporation

Recruiting

Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

EBV-Positive Diffuse Large B-Cell Lymphoma, Nos

China

Search clinical trials for: XPO1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations